Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Steffel

Showing results (121-130 of 204) with videos related to

Pageof 21
Sort By:
Cardiology Journal|August 5, 2020
Familial dilated cardiomyopathy associated with a novel heterozygous RYR2 early truncating variantSarah Costa, Argelia Medeiros-Domingo, Alessio Gasperetti, et al.
Cardiology Journal|March 14, 2022
Predictors of left atrial fibrosis in patients with atrial fibrillation referred for catheter ablationValentina A Rossi, Iva Krizanovic-Grgic, Jan Steffel, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|May 28, 2011
Long-term follow-up of patients with isolated left ventricular noncompaction: role of electrocardiography in predicting poor outcomeJan Steffel, David Hürlimann, Mehdi Namdar, et al.
Circulation|September 27, 2006
Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stentsGiovanni G Camici, Jan Steffel, Alexander Akhmedov, et al.
The American Journal of Medicine|January 18, 2015
Incidence and prognosis of ventricular arrhythmias in patients with congenital left ventricular aneurysms or diverticulaLaurent M Haegeli, Ercüment Ercin, Jan Steffel, et al.
JACC. Advances|July 27, 2025
Long-Term Nonprogression Is a Form of Response to Cardiac Resynchronization TherapySander Trenson, Peter C Kahr, Bert Vandenberk, et al.
International Journal of Cardiology|June 20, 2017
First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trialJan Steffel, Christian T Ruff, Rose A Hamershock, et al.
Journal of the American College of Cardiology|September 10, 2016
Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 AnalysisJan Steffel, Robert P Giugliano, Eugene Braunwald, et al.
Cardiology|July 24, 2023
Efficacy and Safety of Leadless Pacemaker Implantation in OctogenariansDaniel Hofer, François Regoli, Ardan M Saguner, et al.
European Journal of Preventive Cardiology|October 25, 2025
Impact of weight/BMI on clinical and bleeding events in 26 805 atrial fibrillation patients on edoxaban from the Global ETNA-AF RegistryGiuseppe Boriani, Paulus Kirchhof, José Antonio Gordillo de Souza, et al.
Pageof 21

Showing results (121-130 of 204) with videos related to

Sort By:
Pageof 21
Cardiology Journal|August 5, 2020
Familial dilated cardiomyopathy associated with a novel heterozygous RYR2 early truncating variantSarah Costa, Argelia Medeiros-Domingo, Alessio Gasperetti, et al.
Cardiology Journal|March 14, 2022
Predictors of left atrial fibrosis in patients with atrial fibrillation referred for catheter ablationValentina A Rossi, Iva Krizanovic-Grgic, Jan Steffel, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|May 28, 2011
Long-term follow-up of patients with isolated left ventricular noncompaction: role of electrocardiography in predicting poor outcomeJan Steffel, David Hürlimann, Mehdi Namdar, et al.
Circulation|September 27, 2006
Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stentsGiovanni G Camici, Jan Steffel, Alexander Akhmedov, et al.
The American Journal of Medicine|January 18, 2015
Incidence and prognosis of ventricular arrhythmias in patients with congenital left ventricular aneurysms or diverticulaLaurent M Haegeli, Ercüment Ercin, Jan Steffel, et al.
JACC. Advances|July 27, 2025
Long-Term Nonprogression Is a Form of Response to Cardiac Resynchronization TherapySander Trenson, Peter C Kahr, Bert Vandenberk, et al.
International Journal of Cardiology|June 20, 2017
First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trialJan Steffel, Christian T Ruff, Rose A Hamershock, et al.
Journal of the American College of Cardiology|September 10, 2016
Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 AnalysisJan Steffel, Robert P Giugliano, Eugene Braunwald, et al.
Cardiology|July 24, 2023
Efficacy and Safety of Leadless Pacemaker Implantation in OctogenariansDaniel Hofer, François Regoli, Ardan M Saguner, et al.
European Journal of Preventive Cardiology|October 25, 2025
Impact of weight/BMI on clinical and bleeding events in 26 805 atrial fibrillation patients on edoxaban from the Global ETNA-AF RegistryGiuseppe Boriani, Paulus Kirchhof, José Antonio Gordillo de Souza, et al.
Pageof 21